David Meek

David Meek brings over 30 years of experience in the biopharmaceutical industry, having held multiple leadership roles across a range of organizations. He has served as CEO of both public and private biopharma companies, including Mirati Therapeutics, FerGene, and Ipsen.

Before joining Ipsen, David held executive roles such as Executive Vice President and President of Oncology at Baxalta, and Chief Commercial Officer at Endocyte. He also served in global and general management roles at Novartis Pharmaceuticals and Novartis Oncology, after beginning his career at Johnson & Johnson’s Janssen Pharmaceuticals.

David currently serves on the boards of several public biotech companies, including Sobi, uniQure N.V., and Cullinan Therapeutics. He previously served on the boards of Fusion Pharmaceuticals and Entasis Therapeutics until their respective acquisitions. Additionally, he is a board member of the University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences.

He has also contributed to the industry through his service on the boards of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). A decorated commissioned officer in the U.S. Army, David served on active duty and achieved the rank of captain. He is a graduate of the University of Cincinnati.